AZN vs IRTC

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

IRTC presents a stark contrast between fundamental health and growth potential, anchored by a weak Piotroski F-Score of 2/9. While the company demonstrates strong top-line revenue growth (27.1%) and impressive gross margins (70.57%), it is burdened by a high Debt/Equity ratio of 4.79 and a prohibitively expensive Forward P/E of 137.79. Recent earnings beats and a shift toward positive EPS provide a bullish catalyst, but these are offset by bearish insider activity and a complete lack of technical momentum. The stock is currently a speculative growth play rather than a value investment.